Physician profile
Emily Gilbert
NPI 1649627928
$1,811.84
in general payments reported to CMS, 2019-2025
14 companies · $317 in 2025
The $317 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $109 · 2021: $397 · 2022: $294 · 2023: $372 · 2024: $322 · 2025: $317.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,011.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,011.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aurinia Pharma U.S., INC. | $349.77 | 2021-2022 | |
| Ucb, INC. | $344.57 | 2023-2025 | Cimzia, Bimzelx |
| Amgen INC. | $298.01 | 2020-2025 | Otezla, Enbrel, Otezla |
| Novartis Pharmaceuticals Corporation | $223.56 | 2021-2025 | |
| Horizon Therapeutics Plc | $99.55 | 2021-2022 | |
| Genentech, INC. | $98.39 | 2021 | |
| Pfizer INC. | $93.44 | 2023-2025 | |
| Radius Health, INC. | $93.13 | 2025 | Tymlos |
| Lilly USA, LLC | $92.87 | 2023 | Taltz |
| United Therapeutics Corporation | $32.73 | 2023 | Tyvaso |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.48 | 2025 | Ofev |
| Janssen Pharmaceuticals, INC | $23.90 | 2024 | Xarelto |
| Merck Sharp & Dohme LLC | $23.03 | 2025 | Keytruda Qlex, Keytruda |
| Janssen Biotech, INC. | $14.41 | 2024 | Tremfya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Gilbert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.